Not Signed In -
Linezolid |
Zyvox |
Linezolid Systematic (IUPAC) name N-[[3-(3-fluoro-4-morpholinophenyl)- 2-oxooxazolidin-5-yl]methyl]acetamide Identifiers CAS number 165800-03-3 ATC code J01XX08 PubChem 441401 DrugBank APRD01073 Chemical data Formula C16H20N3FO4 Mol. weight 337.346 g/mol Pharmacokinetic data Bioavailability ~100% (oral) Protein binding 31% Metabolism Hepatic 50–70% Half life 4.2–5.4 hours Excretion Renal 80–85% Therapeutic considerations Pregnancy cat. ...
Wikipedia - [full article]
Linezolid Clinical Trials
- Determination of Genetic Relatedness of Linezolid-Resistant VRE Surveillance Cultures
ClinicalTrials.gov Identifier: NCT00475891 - Recruiting
Isolate; Linezolid
- Linezolid in the Treatment of Subjects with Nosocomial Pneumonia Proven to be due to Methicillin-Resistant Staphylococcus Aureus
ClinicalTrials.gov Identifier: NCT00084266 - Recruiting
Pneumonia
- Risk Factors for Linezolid Resistance in Staphylococcus Aureus
ClinicalTrials.gov Identifier: NCT00519025 - Recruiting
Linezolid Resistance; Staphylococcus Aureus
- Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)
ClinicalTrials.gov Identifier: NCT00299520 - Active, not recruiting
Complicated Skin and Skin Structure Infection
- Evaluation Of Linezolid Pk Profil In Burns Patients
ClinicalTrials.gov Identifier: NCT00255996 - Completed
Burns Patient
- Study to Evaluate Eye Function in Patients Taking Linezolid for Two Months or Greater
ClinicalTrials.gov Identifier: NCT00359632 - Not yet recruiting
Optic Nerve Diseases
- Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
ClinicalTrials.gov Identifier: NCT00150332 - Completed
Staphylococcus aureus; Methicillin resistance
- Linezolid in the Treatment of Complicated Skin and Soft Tissue due to Methicillin-Resistant Staphylococcus Aureus
ClinicalTrials.gov Identifier: NCT00087490 - Completed
Staphylococcal Skin Infections; Soft Tissue Infections
- Time To Efficacy and Onset Of Action Of Linezolid
ClinicalTrials.gov Identifier: NCT00147511 - Completed
Gram-Positive Bacterial Infections; Skin and Connective Tissue Diseases
- Towards Reducing Resistance and Hematological Toxicity of Linezolid
ClinicalTrials.gov Identifier: NCT00177723 - Completed
Infection; Adverse Effects
- Linezolid in the Treatment of Hemodialysis Patients with Catheter-Related Gram-Positive Bloodstream Infections
ClinicalTrials.gov Identifier: NCT00108433 - Terminated
Bacteremia; Gram-Positive Bacterial Infections
- Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)
ClinicalTrials.gov Identifier: NCT00303550 - Completed
Skin Diseases, Bacterial
- Microbiologic Response With Linezolid and Vancomycin in Ventilator-Associated Pneumonia Due to Methicillin Resistant Staphylococcus Aureus
ClinicalTrials.gov Identifier: NCT00572559 - Completed
Pneumonia, Ventilator-Associated
- Tigecycline in the Treatment of Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)
ClinicalTrials.gov Identifier: NCT00079976 - Completed
Bacteremia; Pneumonia, Bacterial; Skin Diseases, Bacterial
email this page
print this page
bookmark this page
feedback on this page
